Armour Thyroid is not FDA approved under the modern review system, even though it is a prescription drug sold legally at U.S. pharmacies and remains subject to FDA regulation. The medication predates the 1938 Federal Food, Drug, and Cosmetic Act, which created today’s drug approval pathway. Because no manufacturer ever filed a New Drug Application (NDA) for desiccated porcine thyroid extract, the product reaches patients through a historical regulatory pathway rather than a contemporary safety and effectiveness review.
This guide walks through Armour Thyroid’s unusual standing, explaining how a drug sold at U.S. pharmacies has stayed on shelves without modern FDA review and what that means for anyone weighing treatment options for hypothyroidism.
Armour Thyroid’s Current Regulatory Status in Plain English
Desiccated porcine thyroid extract, sold under the brand Armour Thyroid, is a prescription medication the FDA has never formally approved through an NDA. It is, however, legal to prescribe and dispense in the United States, and it appears in the FDA Orange Book as a “marketed unapproved drug.” That designation sounds contradictory, yet it captures exactly where Armour Thyroid stands today: regulated, available, historically grandfathered in, and never subjected to the clinical trial review required of drugs developed after 1962.
What the Orange Book Listing Actually Means
The Orange Book is the FDA’s official catalog of drug products approved for safety and effectiveness. When a drug appears there as a “marketed unapproved” entry, the FDA signals that the product is on pharmacy shelves but has not cleared the modern approval pathway. Patients sometimes see this designation and assume the drug is counterfeit or experimental, which is not the case. The manufacturer still follows current Good Manufacturing Practices (cGMP), files adverse event reports, and updates labeling as required. What is missing is the rigorous NDA review that newer drugs undergo before reaching market.
- Prescription only: Armour Thyroid requires a valid U.S. prescription from a licensed provider.
- FDA regulated: Manufacturing, labeling, and post-market reporting all fall under FDA oversight.
- Not FDA approved: No clinical trial evidence of safety and effectiveness has been submitted or reviewed through the modern NDA process.
- Active ingredients: Each tablet contains both T4 (levothyroxine) and T3 (liothyronine) hormones derived from pig thyroid glands.
The current manufacturer, AbbVie (through its Allergan subsidiary), produces Armour Thyroid under existing United States Pharmacopeia (USP) monographs for desiccated thyroid. Those monographs set quality standards for the raw ingredient, but they are not a substitute for an FDA approval letter.
The Pre-1938 Origins That Shaped Its Approval Path
Armour Thyroid entered the U.S. market in the 1930s, when thyroid hormone extracts were already sold as treatments for hypothyroidism. At the time, federal drug law required only that medications be free from adulteration and that certain dangerous substances be labeled. The 1938 Federal Food, Drug, and Cosmetic Act changed that by requiring manufacturers to prove safety before marketing a new drug. Because desiccated thyroid was already on pharmacy shelves when the law passed, it was effectively grandfathered in and never had to retroactively prove safety under the new framework.
Why No Manufacturer Ever Filed an NDA
The modern New Drug Application system was not built until the 1962 Kefauver-Harris Amendment, which added a proof of effectiveness requirement on top of the existing safety standard. By then, Armour Thyroid had been in continuous use for roughly three decades. No sponsor had a financial incentive to fund the costly clinical trials needed for an NDA, because the product was already selling without one. That incentive gap is the core reason Armour Thyroid’s FDA approval status has remained frozen for nearly a century.
Forest Laboratories eventually acquired the brand, and AbbVie later absorbed Allergan’s portfolio, which included Armour Thyroid. Through all of those corporate transitions, the product’s regulatory status never changed: still marketed, still legal, still outside the formal approval framework.
That inherited grandfathered status is precisely what made Armour Thyroid a prime target when the FDA later tried to force legacy drugs through modern review.
How the DESI Process Tried, and Failed, to Retire It
In the 1960s the FDA launched the Drug Efficacy Study Implementation (DESI) review to catch up on thousands of pre-1962 drugs that had never been evaluated for effectiveness. DESI notices were published drug by drug, sometimes concluding that older products were “not generally recognized as safe and effective.” In 1997 the FDA published a DESI notice reaching exactly that conclusion for desiccated thyroid. By every modern regulatory standard, the FDA had just declared Armour Thyroid ineffective.
The Gray-Zone Outcome
Rather than pull the product from shelves, the agency allowed Armour Thyroid to remain on the market while manufacturers weighed next steps. The FDA’s own guidance on marketed unapproved drugs leaves room for continued distribution when withdrawal would cause patient harm or when manufacturers are working toward compliance. In Armour Thyroid’s case, the agency never issued a formal withdrawal order, and the brand kept being shipped. That decision created the defining quirk of Armour Thyroid’s regulatory identity: a drug the FDA has effectively said is not proven effective, yet still permits to be sold.
Warning: A drug that fails a DESI effectiveness review is not necessarily unsafe, but the absence of modern trial data means long-term outcomes are less documented than for newer alternatives.
For patients, this history explains why Armour Thyroid can be prescribed, why insurance coverage is often uncertain, and why the FDA approval status looks confusing on paper.
Approval remains a sticking point because the distinction quietly shapes how insurers, pharmacists, and patients weigh their options next.
FDA-Regulated Does Not Mean FDA-Approved
Patients frequently hear that Armour Thyroid is “FDA regulated” and assume that is the same as being “FDA approved.” It is not. FDA regulation covers a wide range of activities, including manufacturing inspections, adverse event reporting, and labeling requirements. FDA approval, by contrast, is a specific determination made after reviewing clinical trial evidence submitted through an NDA or its equivalent. A drug can be heavily regulated for decades and still never receive formal approval.
What Each Status Means in Practice
- FDA approved: The agency has reviewed controlled clinical trial data and concluded the drug is safe and effective for its labeled use.
- FDA regulated: The drug is subject to manufacturing, labeling, and reporting rules, regardless of formal approval.
- Marketed unapproved: A regulatory category that lets older drugs stay on the shelf while remaining outside the modern approval framework.
- Compounded: A separate category covering drugs mixed by compounding pharmacies, which does not apply to Armour Thyroid.
Understanding this distinction helps when reading marketing claims about any older prescription medication. Words like “trusted for 80 years” or “physician prescribed” do not signal approval; they signal history and regulation, which are different things.
Comparing Armour Thyroid to Modern FDA-Approved Alternatives
Synthetic levothyroxine, sold under brand names such as Synthroid, Levoxyl, and Tirosint, holds full NDA approval and is the first-line therapy recommended by major endocrinology guidelines. Levothyroxine replaces only the T4 hormone, which the body then converts into T3 as needed. Liothyronine (brand name Cytomel) is FDA approved as a standalone T3 medication, but it is rarely prescribed alone because T4-only therapy generally normalizes thyroid levels in most patients.
Head-to-Head Snapshot
| Feature | Armour Thyroid | Synthetic Levothyroxine |
|---|---|---|
| FDA approval status | Marketed unapproved (DESI-era) | Fully NDA approved |
| Hormones provided | T4 + T3 from porcine source | T4 only (synthetic) |
| Source | Desiccated pig thyroid gland | Synthetic manufacturing |
| Guideline recommendation | Case-by-case clinical choice | First-line standard of care |
| Insurance coverage | Often limited or off-formulary | Generally covered |
Clinical practice guidelines from the American Thyroid Association and the Endocrine Society continue to favor levothyroxine monotherapy for most patients, citing consistent dosing, predictable lab results, and large-scale outcome data. Armour Thyroid remains a case-by-case clinical decision, often used when a patient on levothyroxine still reports persistent symptoms despite normalized lab values.
Yet the prescribing logic that justifies Armour Thyroid rarely survives a trip to the pharmacy, where coverage rules apply a second filter.
What the Regulatory Nuance Means at the Pharmacy Counter
At the pharmacy counter, Armour Thyroid looks like any other prescription. Your pharmacist can fill it, your insurance may or may not cover it, and your prescriber can write for it on-label or off-label depending on clinical judgment. None of those steps require FDA approval paperwork, because the prescription system is separate from the brand approval system.
Practical Tips for Patients
- Confirm pharmacy stock: Call ahead, because not every chain stocks Armour Thyroid consistently.
- Ask about prior authorization: Insurance plans often require extra documentation before covering this medication.
- Track symptoms and labs together: Bring your most recent TSH, Free T4, and Free T3 results to every appointment.
- Discuss switching options: If cost is a barrier, ask whether generic levothyroxine plus lifestyle changes might meet your goals.
- Report unusual side effects: Use the FDA MedWatch program, since post-market reporting is one of the few formal oversight channels for marketed unapproved drugs.
Prescribing decisions rest on symptom control, lab targets, and personal preference rather than approval paperwork. Your prescriber weighs whether combination T4/T3 therapy fits your specific thyroid profile, not whether the FDA has stamped a number on the brand.
Final Word
Armour Thyroid occupies a regulatory category that confuses even experienced patients: legally prescribed, FDA regulated, and listed in the Orange Book, yet never formally approved through the modern NDA process. That historical status does not automatically make the medication unsafe, but it does mean the long-term evidence base is thinner than what supports fully approved alternatives. The most informed move you can make is to bring your lab results, your symptom list, and your questions about coverage to a prescriber who treats thyroid conditions regularly, and to make the choice together.
FAQ
Is Armour Thyroid approved by the FDA?
No. Armour Thyroid has not gone through the modern FDA approval process and has no New Drug Application on file. It is listed in the FDA’s Orange Book as a marketed unapproved drug, meaning it is legal and regulated but never formally reviewed for safety and effectiveness under current standards.
Why is Armour Thyroid not FDA approved?
Armour Thyroid was already on the market in the 1930s, before the 1938 Federal Food, Drug, and Cosmetic Act created today’s approval framework. The 1962 Kefauver-Harris Amendment later added effectiveness requirements, but no manufacturer has ever submitted clinical trial data for desiccated thyroid extract, so the product remains grandfathered outside the modern approval system.
Is Armour Thyroid legal in the United States?
Yes. Armour Thyroid is a prescription drug that can be legally dispensed at any licensed U.S. pharmacy. Its marketed unapproved status means it is regulated but not formally approved, which is a legal category distinct from banned or counterfeit medications.
Has Armour Thyroid been discontinued by the FDA?
No. Armour Thyroid is still manufactured by AbbVie/Allergan and remains available by prescription. A 1997 FDA DESI notice declared desiccated thyroid “not generally recognized as safe and effective,” yet the agency has not issued a withdrawal order, so the product continues to be sold.
What is the difference between Armour Thyroid and FDA-approved levothyroxine?
Levothyroxine (Synthroid, Levoxyl, Tirosint, and generics) is fully FDA approved and provides only T4, which the body converts into T3 as needed. Armour Thyroid provides both T4 and T3 derived from porcine thyroid glands, but it has never gone through formal FDA approval and is generally not the first-line therapy recommended by endocrinology guidelines.
Can a doctor still prescribe Armour Thyroid?
Yes. Any licensed U.S. prescriber can write a prescription for Armour Thyroid. The decision is based on clinical judgment, lab results, and symptom response, not on the drug’s approval status. Many prescribers reserve Armour Thyroid for patients who continue to have symptoms despite optimized levothyroxine therapy.
